Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-06-12 4:55 pm Purchase |
2025-06-05 | 13G | Xilio Therapeutics, Inc. XLO |
Frazier Life Sciences Public Fund, L.P. | 5,747,193 9.900% |
5,747,193 (New Position) |
Filing History |
| 2025-06-04 4:51 pm Purchase |
2025-05-28 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO |
Frazier Life Sciences Public Fund, L.P. | 5,500,812 9.900% |
5,500,812 (New Position) |
Filing History |
| 2025-05-23 4:07 pm Purchase |
2025-05-16 | 13G | Aura Biosciences, Inc. AURA |
Frazier Life Sciences Public Fund, L.P. | 6,315,678 9.900% |
6,315,678 (New Position) |
Filing History |
| 2025-05-15 09:55 am Sale |
2025-03-31 | 13G | Trevi Therapeutics, Inc. TRVI |
Frazier Life Sciences Public Fund, L.P. | 10,259,409 10.600% |
-405,365 (-3.80%) |
Filing History |
| 2025-05-15 09:52 am Purchase |
2025-03-31 | 13G | Savara Inc. SVRA |
Frazier Life Sciences Public Fund, L.P. | 11,462,301 6.600% |
2,801,922 (+32.35%) |
Filing History |
| 2025-05-15 09:44 am Purchase |
2025-03-31 | 13G | Erasca, Inc. ERAS |
Frazier Life Sciences Public Fund, L.P. | 22,575,851 8.000% |
6,359,635 (+39.22%) |
Filing History |
| 2025-05-15 09:42 am Sale |
2025-03-31 | 13G | ORIC Pharmaceuticals, Inc. ORIC |
Frazier Life Sciences Public Fund, L.P. | 1,410,193 2.000% |
-2,732,662 (-65.96%) |
Filing History |
| 2025-05-15 09:39 am Purchase |
2025-03-31 | 13G | Palvella Therapeutics, Inc. PVLA |
Frazier Life Sciences Public Fund, L.P. | 690,012 6.300% |
114,120 (+19.82%) |
Filing History |
| 2025-05-13 4:22 pm Purchase |
2025-05-09 | 13D | Phathom Pharmaceuticals, Inc. PHAT |
Frazier Life Sciences Public Fund, L.P. | 14,429,990 19.900% |
1,641,280 (+12.83%) |
Filing History |
| 2025-05-05 09:43 am Purchase |
2025-04-28 | 13G | Jade Biosciences, Inc. JBIO |
Frazier Life Sciences Public Fund, L.P. | 1,772,116 5.500% |
1,772,116 (New Position) |
Filing History |
| 2025-04-29 09:59 am Purchase |
2025-04-25 | 13G | Maze Therapeutics, Inc. MAZE |
Frazier Life Sciences Public Fund, L.P. | 4,451,339 10.200% |
322,339 (+7.81%) |
Filing History |
| 2025-04-29 09:58 am Purchase |
2025-03-31 | 13G | Maze Therapeutics, Inc. MAZE |
Frazier Life Sciences Public Fund, L.P. | 4,129,000 9.400% |
935,100 (+29.28%) |
Filing History |
| 2025-04-04 12:39 pm Purchase |
2025-04-01 | 13G | Mereo BioPharma Group plc MREO |
Frazier Life Sciences Public Fund, L.P. | 40,349,315 5.100% |
40,349,315 (New Position) |
Filing History |
| 2025-02-14 11:27 am Sale |
2025-01-31 | 13G | AnaptysBio, Inc. ANAB |
Frazier Life Sciences Public Fund, L.P. | 463,241 1.500% |
-1,192,054 (-72.01%) |
Filing History |
| 2025-02-14 11:25 am Sale |
2024-12-31 | 13G | AnaptysBio, Inc. ANAB |
Frazier Life Sciences Public Fund, L.P. | 1,655,295 5.400% |
-261,896 (-13.66%) |
Filing History |
| 2025-02-14 11:22 am Sale |
2024-12-31 | 13G | Eledon Pharmaceuticals, Inc. ELDN |
Frazier Life Sciences Public Fund, L.P. | 1,176,735 2.000% |
-2,384,909 (-66.96%) |
Filing History |
| 2025-02-14 11:21 am Purchase |
2024-12-31 | 13G | Trevi Therapeutics, Inc. TRVI |
Frazier Life Sciences Public Fund, L.P. | 10,664,774 11.900% |
3,283,684 (+44.49%) |
Filing History |
| 2025-02-14 11:11 am Sale |
2024-12-31 | 13G | Puma Biotechnology, Inc. PBYI |
Frazier Life Sciences Public Fund, L.P. | 0 0.000% |
-2,631,713 (Position Closed) |
Filing History |
| 2025-02-14 11:07 am Unchanged |
2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
Frazier Life Sciences Public Fund, L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2025-02-10 10:55 am Purchase |
2025-02-03 | 13G | Maze Therapeutics, Inc. MAZE |
Frazier Life Sciences Public Fund, L.P. | 3,193,900 7.300% |
3,193,900 (New Position) |
Filing History |